- Home
- OBIO vs CDXS Comparison
OBIO vs CDXS Comparison
Compare OBIO & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- CDXS
- Stock Information
- Founded
- OBIO 2017
- CDXS 2002
- Country
- OBIO United States
- CDXS United States
- Employees
- OBIO N/A
- CDXS N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- CDXS Major Chemicals
- Sector
- OBIO Health Care
- CDXS Industrials
- Exchange
- OBIO Nasdaq
- CDXS Nasdaq
- Market Cap
- OBIO 151.3M
- CDXS 201.3M
- IPO Year
- OBIO N/A
- CDXS 2010
- Fundamental
- Price
- OBIO $2.85
- CDXS $2.30
- Analyst Decision
- OBIO Strong Buy
- CDXS Buy
- Analyst Count
- OBIO 5
- CDXS 2
- Target Price
- OBIO $14.20
- CDXS $11.00
- AVG Volume (30 Days)
- OBIO 193.1K
- CDXS 1.0M
- Earning Date
- OBIO 05-12-2025
- CDXS 05-14-2025
- Dividend Yield
- OBIO N/A
- CDXS N/A
- EPS Growth
- OBIO N/A
- CDXS N/A
- EPS
- OBIO N/A
- CDXS N/A
- Revenue
- OBIO $2,886,000.00
- CDXS $49,815,000.00
- Revenue This Year
- OBIO $21.38
- CDXS $2.41
- Revenue Next Year
- OBIO $31.89
- CDXS $34.28
- P/E Ratio
- OBIO N/A
- CDXS N/A
- Revenue Growth
- OBIO 30.23
- CDXS N/A
- 52 Week Low
- OBIO $2.37
- CDXS $1.90
- 52 Week High
- OBIO $8.87
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- OBIO 49.08
- CDXS 44.61
- Support Level
- OBIO $2.61
- CDXS $2.30
- Resistance Level
- OBIO $3.02
- CDXS $2.56
- Average True Range (ATR)
- OBIO 0.18
- CDXS 0.20
- MACD
- OBIO 0.04
- CDXS -0.01
- Stochastic Oscillator
- OBIO 60.19
- CDXS 46.67
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About CDXS Codexis Inc.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.